Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

BACKGROUND: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formation of new blood vessels. METH...

詳細記述

保存先:
書誌詳細
出版年:Genome Med
主要な著者: Höglander, Elen Kristine, Nord, Silje, Wedge, David C., Lingjærde, Ole Christian, Silwal-Pandit, Laxmi, Gythfeldt, Hedda vdL, Vollan, Hans Kristian Moen, Fleischer, Thomas, Krohn, Marit, Schlitchting, Ellen, Borgen, Elin, Garred, Øystein, Holmen, Marit M., Wist, Erik, Naume, Bjørn, Van Loo, Peter, Børresen-Dale, Anne-Lise, Engebraaten, Olav, Kristensen, Vessela
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2018
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6262977/
https://ncbi.nlm.nih.gov/pubmed/30497530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-018-0601-y
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料